Penetrating agent used for peritoneal dialysate and dialysate thereof

Abstract

The invention provides a penetrating agent used for a peritoneal dialysate and a dialysate thereof, belonging to the research field of the peritoneal dialysate in peritoneal dialysis treatment of end stage renal disease. The penetrating agent is 2.5-7.5% of maltose aqueous solution, preferably 2.5%, 4.25% or 7.5% of maltose aqueous solution. Per 100 ml of the dialysate prepared by the penetrating agent comprises the following components: 2.5-7.5g of maltose, 535mg of sodium chloride, 448g of sodium lactate, 25.7mg of calcium chloride and 5.08g of magnesium chloride; and preferably, each 100ml of the dialysate comprises 2.5g, 4.25g or 7.5g of maltose. The dialysate prepared by the penetrating agent has good biocompatibility and favorable price, can maintain stable ultrafiltration effect, and generates little side effect in vivo after metabolization.

Description

technical field [0001] The invention belongs to the research field of peritoneal dialysis fluid in end-stage renal disease peritoneal dialysis treatment. The invention relates to an osmotic agent for peritoneal dialysis fluid and the dialysis fluid thereof. Background technique [0002] Peritoneal dialysis is one of the effective treatments for end-stage renal disease. In peritoneal dialysis, the peritoneum acts as a semipermeable membrane with a large number of blood vessels and capillaries on its surface. During dialysis, peritoneal dialysis fluid is injected into the peritoneal cavity through the peritoneal dialysis tube, and the solute is exchanged between the peritoneal dialysis fluid and blood vessels. At the same time, the peritoneal dialysis fluid provides a certain osmotic pressure, and the excess fluid in the blood vessels will be ultrafiltered into the peritoneal cavity, thereby achieving water , electrolyte and acid-base balance. The osmotic agent plays a majo...

AI Technical Summary

Problems solved by technology

2. High concentration of glucose and glucose degradation products can damage peritoneal mesothelial cells [1]

3. The rapid absorption of glucose in the peritoneal cavity will lead to the reduction or disappearance of the osmotic gradient, resulting in a decrease in the amount of ultrafiltration, and even reverse ultrafiltration

4. Since the glucose in the peritoneal dialysis fluid is not completely stable, it can be degraded into 5-hydroxymethanefurfural, which is easy to combine with anionic substances to form Schiff’s base. This compound is an early glycosylation product that will change Properties of many tissue components that ultimately lead to irreversible changes in peritoneal structure and function, resulting in decreased peritoneal ultrafiltration [4] , and eventually ultrafiltration failure

However, the following defects limit the clinical application of amino acid peritoneal dialysis solution

1. The application of amino acid dialysate will cause mild gastrointestinal reactions, such as nausea, vomiting, etc., while suppressing appetite and causing metabolic acidosis

2. Amino acid dialysate changes the charge properties of the peritoneal surface, increases blood urea nitrogen levels, inhibits the function of white blood cells, and aggravates homocysteinemia, thereby increasing the risk of atherosclerosis

Its disadvantages are: 1. In the use of icodextrin peritoneal dialysis solution, due to the limitation of the measurement method, falsely high blood sugar values ​​will be produced, which may cause serious hypoglycemia or death. [10]

3. Due to its high price, its clinical use is greatly limited, especially in developing countries

Images